152 related articles for article (PubMed ID: 23711895)
21. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
Colonno R; Rose R; McLaren C; Thiry A; Parkin N; Friborg J
J Infect Dis; 2004 May; 189(10):1802-10. PubMed ID: 15122516
[TBL] [Abstract][Full Text] [Related]
22. Atazanavir: a review of its use in the management of HIV-1 infection.
Croom KF; Dhillon S; Keam SJ
Drugs; 2009 May; 69(8):1107-40. PubMed ID: 19496633
[TBL] [Abstract][Full Text] [Related]
23. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Péré H; Charpentier C; Mbelesso P; Dandy M; Matta M; Moussa S; De Dieu Longo J; Grésenguet G; Abraham B; Bélec L
AIDS Res Hum Retroviruses; 2012 Apr; 28(4):315-23. PubMed ID: 21942692
[TBL] [Abstract][Full Text] [Related]
24. Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection.
Sungkanuparph S; Sukasem C; Manosuthi W; Wiboonchutikul S; Piyavong B; Chantratita W
J Clin Virol; 2008 Nov; 43(3):284-6. PubMed ID: 18701346
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
26. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Daar ES; Tierney C; Fischl MA; Sax PE; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Pappa KA; Woodward WC; Patterson K; Bolivar H; Benson CA; Collier AC;
Ann Intern Med; 2011 Apr; 154(7):445-56. PubMed ID: 21320923
[TBL] [Abstract][Full Text] [Related]
27. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Vora S; Marcelin AG; Günthard HF; Flandre P; Hirsch HH; Masquelier B; Zinkernagel A; Peytavin G; Calvez V; Perrin L; Yerly S;
AIDS; 2006 Jan; 20(1):35-40. PubMed ID: 16327317
[TBL] [Abstract][Full Text] [Related]
28. Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
Santoro MM; Bertoli A; Lorenzini P; Ceccherini-Silberstein F; Gianotti N; Mussini C; Torti C; Di Perri G; Barbarini G; Bini T; Melzi S; Caramello P; Maserati R; Narciso P; Micheli V; Antinori A; Perno CF;
Infection; 2009 Jun; 37(3):233-43. PubMed ID: 19169632
[TBL] [Abstract][Full Text] [Related]
29. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
30. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
Lambert-Niclot S; Masquelier B; Cohen Codar I; Soulie C; Delaugerre C; Morand-Joubert L; Charpentier C; Ferre V; Plantier JC; Montes B; Carret S; Perrot V; Peytavin G; Costagliola D; Calvez V; Marcelin AG;
J Antimicrob Chemother; 2012 Oct; 67(10):2487-93. PubMed ID: 22733652
[TBL] [Abstract][Full Text] [Related]
31. Atazanavir: a review of its use in the management of HIV infection.
Swainston Harrison T; Scott LJ
Drugs; 2005; 65(16):2309-36. PubMed ID: 16266202
[TBL] [Abstract][Full Text] [Related]
32. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
Røge BT; Katzenstein TL; Nielsen HL; Gerstoft J
HIV Med; 2003 Jan; 4(1):38-47. PubMed ID: 12534958
[TBL] [Abstract][Full Text] [Related]
34. [Viral resistance and genetic barrier of atazanavir].
Mendoza CD; Garrido C; Treviño A; Anta L; Poveda E; Soriano V
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():28-33. PubMed ID: 20116614
[TBL] [Abstract][Full Text] [Related]
35. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
Sista P; Wasikowski B; Lecocq P; Pattery T; Bacheler L
J Clin Virol; 2008 Aug; 42(4):405-8. PubMed ID: 18472298
[TBL] [Abstract][Full Text] [Related]
36. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P;
BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730
[TBL] [Abstract][Full Text] [Related]
37. Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
Thompson JA; Kityo C; Dunn D; Hoppe A; Ndashimye E; Hakim J; Kambugu A; van Oosterhout JJ; Arribas J; Mugyenyi P; Walker AS; Paton NI;
Clin Infect Dis; 2019 Mar; 68(7):1184-1192. PubMed ID: 30060027
[TBL] [Abstract][Full Text] [Related]
38. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
[TBL] [Abstract][Full Text] [Related]
39. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.
Brindeiro PA; Brindeiro RM; Mortensen C; Hertogs K; De Vroey V; Rubini NP; Sion FS; De Sá CA; Machado DM; Succi RC; Tanuri A
J Clin Microbiol; 2002 Dec; 40(12):4512-9. PubMed ID: 12454144
[TBL] [Abstract][Full Text] [Related]
40. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
